Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
92.25
-2.10 (-2.23%)
Feb 21, 2025, 4:00 PM EST - Market closed
Blueprint Medicines Stock Forecast
Stock Price Forecast
The 18 analysts with 12-month price forecasts for Blueprint Medicines stock have an average target of 123.61, with a low estimate of 76 and a high estimate of 168. The average target predicts an increase of 33.99% from the current stock price of 92.25.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Blueprint Medicines stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 7 | 6 | 6 |
| Buy | 6 | 6 | 7 | 7 | 7 | 7 |
| Hold | 4 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 17 | 18 | 19 | 20 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $125 | Buy | Reiterates | $125 | +35.50% | Feb 14, 2025 |
| Needham | Needham | Strong Buy Reiterates $133 | Strong Buy | Reiterates | $133 | +44.17% | Feb 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +46.34% | Feb 14, 2025 |
| Needham | Needham | Strong Buy Reiterates $133 | Strong Buy | Reiterates | $133 | +44.17% | Feb 13, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $126 → $129 | Buy | Maintains | $126 → $129 | +39.84% | Feb 4, 2025 |
Financial Forecast
Revenue This Year
734.17M
from 508.82M
Increased by 44.29%
Revenue Next Year
972.68M
from 734.17M
Increased by 32.49%
EPS This Year
-0.80
from -1.07
EPS Next Year
1.95
from -0.80
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 834.8M | 1.2B | 1.5B | ||
| Avg | 734.2M | 972.7M | 1.2B | ||
| Low | 560.7M | 744.5M | 988.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 64.1% | 61.0% | 49.8% | ||
| Avg | 44.3% | 32.5% | 23.2% | ||
| Low | 10.2% | 1.4% | 1.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.06 | 6.04 | 9.16 | ||
| Avg | -0.80 | 1.95 | 4.49 | ||
| Low | -3.60 | -1.22 | 1.05 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 370.4% | ||
| Avg | - | - | 130.6% | ||
| Low | - | - | -46.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.